BAJAJHCARE · NSE
Bajaj Healthcare Limited
₹330.55
+0.67% (+₹2.2)
Prev. close
₹328.35
Volume
42,148
Delivery %
57.0%
As of
18 Sept 2026
Price history
No analyst calls on this stock in the last 90 days yet.
Explore by date range →Analyst opinions
Fundamentals
About Bajaj Healthcare Limited
Bajaj HealthCare Limited, a pharmaceutical company, develops, manufactures, markets, and sells active pharmaceutical ingredient, intermediates, and finished dosage forms and nutraceuticals for pharmaceutical, nutraceuticals, and food industries in India and internationally. The company offers active pharmaceutical ingredient in various therapeutic categories, including anthelmintic, anti viral, anti coagulant, vitamin c, anti arthritis, atypical antipsychotic agent, anti convulsant, vasoprotective, disinfectant, anti asthamatic, neuro protective, anti histamine, iron chelator, vasoprotective, urinary tract infection, anti migraine, anti rheumatic, antibiotic, anti tussive, weight reducing, hemorheologic agent, vasodilator, anti psychotic, beta agonist, gastroretentive drug, and antagonist. It also provides 2-amino-3,5-dibromobenzaldehyde, bromoethyl theophylline, calcium phosphoryl choline chloride, 4-hydrazinobenzoic acid and octopamine HCL, 8- chloro theophylline, chlorohexanone, theobromine, hesperidin, 5-amino-2,4,6-triiodoisophthaloyl dichloride, 3-methyl xanthine, 3-methyl-7-(2-butyn-1-yl)-8- bromo xanthine, 8 bromo-3-methyl xanthine, 4,5-dinitroaniline, 4,5-dichloro-2-nitroaniline, and 2-amino -4- hydroxyacetophenone. In addition, it offers nutraceuticals; and formulations in the form of tablets, capsules, sachets, and vials, as well as impurities. Bajaj HealthCare Limited was incorporated in 1993 and is based in Thane, India.
Details
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
CEO
Mr. Sajankumar Rameshwarlal Bajaj
Headquarters
Thane
Employees
949
Website
bajajhealth.comExchange
View on NSE ↗Key stats
Market cap
₹1,112.80 Cr
P/E ratio (TTM)
47.3
Dividend yield
0.46%
EPS (TTM)
₹6.99
Beta (1Y · daily vs NIFTY 50)
1.25
Beta (5Y · monthly vs NIFTY 50)
1.18
Shares float
1.25 Cr
EPS · quarter ended Jun 2026
₹4.06
Financial Performance
01 · Financials
Revenue for Mar 2021–Mar 2022 is as filed with BSE (standalone), and the first plotted growth figure is computed against Mar 2020 revenue as filed with BSE; the two sources' revenue definitions differ by 4.3% on Mar 2023. FY21 growth needs FY20 filings, which the data source doesn't provide. EBITDA is omitted from this chart: coverage begins inside the plotted window, and every plotted period must carry a complete point set — the P&L table below has the available figures.
02 · Earnings Per Share (EPS)
03 · Dividend Profile
Growth compares completed fiscal-year dividend totals on the company's own calendar: April–March (Indian FY), taken from its reported period-ends. Payout ledger: NSE corporate actions.
04 · Operating Efficiency (Growth Rates)
Balance-sheet-based · pre-FY23 not filed in verifiable form
05 · Capital Structure & Asset Utilization
Pre-FY23 not filed in verifiable form
Asset turnover needs a prior year of assets — omitted for the earliest available year.
06 · Asset Base Composition
Pre-FY23 not filed in verifiable form
07 · Debt Level & Coverage
Pre-FY23 not filed in verifiable form
08 · Profit & Loss
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| ₹656.98 Cr | ₹679.89 Cr | ₹673.29 Cr | ₹473.42 Cr | ₹542.60 Cr | ₹611.03 Cr | |
| EBITDA | — | ₹119.95 Cr | ₹121.94 Cr | ₹43.83 Cr | ₹101.83 Cr | ₹78.71 Cr |
| ₹83.11 Cr | ₹71.39 Cr | ₹43.02 Cr | ₹-83.79 Cr | ₹39.50 Cr | ₹15.77 Cr | |
| Diluted EPS | ₹60.23 | ₹25.87 | ₹15.59 | ₹-30.36 | ₹13.12 | ₹4.97 |
Total expenses (as filed), Employee benefit expense, Depreciation & amortisation, Other expenses, EBITDA, Pretax income, Tax provision, Interest expense, Other income have filed figures for only some of the years shown — no further verified source covers the rest, so those years are left blank rather than estimated.
09 · Balance Sheet
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| ₹526.00 Cr | ₹721.00 Cr | ₹898.00 Cr | ₹765.00 Cr | ₹833.00 Cr | ₹923.00 Cr | |
| — | — | ₹415.24 Cr | ₹332.82 Cr | ₹223.25 Cr | ₹249.09 Cr | |
| Stockholders' equity | ₹259.00 Cr | ₹329.00 Cr | ₹368.00 Cr | ₹279.00 Cr | ₹466.00 Cr | ₹533.00 Cr |
Current assets, Inventory, Trade receivables, Cash & equivalents, Non-current assets, CWIP, Others, Total debt, Long-term debt, Current (short-term) debt have filed figures for only some of the years shown — no further verified source covers the rest, so those years are left blank rather than estimated.
Annual only — the data source doesn’t publish quarterly balance-sheet detail for most NSE-listed companies.
10 · Cash Flow Statement
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| — | ₹68.59 L | ₹-22.32 Cr | ₹92.29 Cr | ₹21.62 Cr | ₹58.08 Cr | |
| Investing cash flow | — | ₹-74.80 Cr | ₹-93.43 Cr | ₹-11.24 Cr | ₹-14.82 Cr | ₹-47.78 Cr |
| — | ₹61.85 Cr | ₹131.50 Cr | ₹-96.60 Cr | ₹-6.38 Cr | ₹24.33 Cr | |
| Capital expenditure | — | ₹-74.23 Cr | ₹-93.59 Cr | ₹-30.29 Cr | ₹-11.54 Cr | ₹-43.35 Cr |
| End cash position | — | ₹1.98 Cr | ₹17.72 Cr | ₹2.17 Cr | ₹2.60 Cr | ₹37.24 Cr |
Operating cash flow, Depreciation & amortization, Change in working capital, Investing cash flow, Financing cash flow, Dividends paid, Capital expenditure, End cash position have filed figures for only some of the years shown — no further verified source covers the rest, so those years are left blank rather than estimated.
Annual only — the data source has no quarterly cash-flow-statement coverage.
11 · Shareholding Pattern
NSE, quarterly
| Line item | Nov 21–Mar 22(3Q) | Jun 22–Sep 22(2Q) | Dec 22 | Mar 23–Jun 23(2Q) | Sep 23 | Dec 23–Jun 24(3Q) | Sep 24–Dec 25(7Q) | Mar 26–Mar 26(2Q) | Jun 26 |
|---|---|---|---|---|---|---|---|---|---|
| Promoter | 67.26% | 67.30% | 67.42% | 67.49% | 67.69% | 67.73% | 59.19% | 58.29% | 58.59% |
| Public | 32.74% | 32.70% | 32.58% | 32.51% | 32.31% | 32.27% | 40.81% | 41.71% | 41.41% |
| Employee trusts | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Source: NSE quarterly shareholding-pattern filings, collapsed to periods where the reported percentages held steady — a column spanning several quarters means no change was filed across them. No FII/DII sub-split available from this source — Public includes all non-promoter, non-employee-trust holders.
12 · Peer Comparison
Healthcare
| Company | ||||||||
|---|---|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | ₹4.48 L Cr | ₹1,837.3 | 37.0 | 5.36 | 13.7% | 0.06 | +11.9% | +11.4% |
| Divi's Laboratories Limited | ₹2.47 L Cr | ₹9,375 | 83.3 | 14.77 | 15.3% | 0.00 | +12.3% | +53.4% |
| Torrent Pharmaceuticals Limited | ₹1.83 L Cr | ₹4,875 | 76.9 | 21.82 | 25.8% | 1.79 | +21.5% | +37.4% |
| Apollo Hospitals Enterprise Limited | ₹1.26 L Cr | ₹8,944.5 | 60.4 | 13.30 | 20.5% | 0.90 | +15.7% | +13.9% |
| Lenskart Solutions Limited | ₹1.18 L Cr | ₹707.2 | 179.9 | 13.48 | 5.6% | 0.35 | +35.4% | — |
| Zydus Lifesciences Limited | ₹1.13 L Cr | ₹1,160 | 25.3 | 4.18 | 18.6% | 0.46 | +18.4% | +10.7% |
| Cipla Limited | ₹1.10 L Cr | ₹1,376.3 | 32.5 | 3.19 | 11.3% | 0.02 | +2.1% | -11.8% |
| Laurus Labs Limited | ₹1.05 L Cr | ₹1,954 | 96.4 | 19.86 | 16.8% | 0.48 | +22.0% | +111.6% |
| Max Healthcare Institute Limited | ₹1.01 L Cr | ₹1,049.3 | 69.8 | 9.39 | 13.4% | 0.32 | +19.0% | -10.6% |
| Dr. Reddy's Laboratories Limited | ₹97,876.16 Cr | ₹1,185 | 29.6 | 2.60 | 11.4% | 0.21 | +3.2% | -10.4% |
| Manipal Health Enterprises Limited | ₹97,364.22 Cr | ₹738.95 | 146.6 | 11.56 | 7.8% | 1.53 | +18.0% | — |
| Bajaj Healthcare Limited | ₹1,112.80 Cr | ₹330.55 | 47.3 | 2.09 | 3.0% | 0.47 | +12.6% | -22.6% |
Ranked by market cap within Healthcare, same metrics as the Fundamentals screener. Click a column to sort.
Documents
Annual reports
Show all 15
Concall transcripts
Official documents linked from their sources — offer documents as filed with SEBI (sebi.gov.in), annual reports and earnings-call transcripts as published on BSE (bseindia.com) and NSE (nseindia.com). Links open the source's own hosting; nothing is re-hosted here.
Index membership
2 indices
Weight is BSE’s own published index weight. Indices without weight data are listed without one, in alphabetical order after the weighted ones.
Dividend stocks alert! Last chance to qualify- Kalyan Jewellers, Aarti Industries, Blue Jet, Bajaj Healthcare, more
Livemint · 8 days ago